Tandem Diabetes Care (LTS:0M0F) ROC (Joel Greenblatt) %: -26.55% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0M0F Tandem Diabetes Care Inc LTS:0M0F
68 GF Score
Price $16.44
GF Value $29.13
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care ROC (Joel Greenblatt) %?

Tandem Diabetes Care LTS:0M0F -2.72% 68 ROC (Joel Greenblatt) % is -26.55% as of Mar. 2026. GuruFocus rates LTS:0M0F with a GF Score™ of 68/100 and a GF Value™ of $29.13 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 838 Medical Devices & Instruments companies, Tandem Diabetes Care ranks worse than 67.42% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Tandem Diabetes Care's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -26.55%.

The historical rank and industry rank for Tandem Diabetes Care's ROC (Joel Greenblatt) % or its related term are showing as below:

LTS:0M0F' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -453.88   Med: -69.8   Max: 14.94
Current: -35.65

During the past 13 years, Tandem Diabetes Care's highest ROC (Joel Greenblatt) % was 14.94%. The lowest was -453.88%. And the median was -69.80%.

LTS:0M0F's ROC (Joel Greenblatt) % is ranked worse than
67.42% of 838 companies
in the Medical Devices & Instruments industry
Industry Median: 4.145 vs LTS:0M0F: -35.65

Tandem Diabetes Care's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Tandem Diabetes Care  (LTS:0M0F) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Tandem Diabetes Care ROC (Joel Greenblatt) % Related Terms


Tandem Diabetes Care ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care ROC (Joel Greenblatt) % Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.94 -43.93 -80.63 -32.73 -71.48

Tandem Diabetes Care Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -189.47 -89.75 -37.95 7.46 -26.55

LTS:0M0F vs CNMD, AORT, LMRI: ROC (Joel Greenblatt) % Comparison

For the Medical Devices subindustry, Tandem Diabetes Care's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tandem Diabetes Care ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Tandem Diabetes Care's ROC (Joel Greenblatt) % falls into.


LTS:0M0F
68GF Score
Tandem Diabetes Care Inc LTS:0M0F
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(165.491 + 128.769 + 31.217) - (68.079 + 9.527 + 145.646)
=102.225

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(140.672 + 126.4 + 49.772) - (79.098 + 8.954 + 139.798)
=88.994

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Tandem Diabetes Care for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-72.996/( ( (179.752 + max(102.225, 0)) + (178.99 + max(88.994, 0)) )/ 2 )
=-72.996/( ( 281.977 + 267.984 )/ 2 )
=-72.996/274.9805
=-26.55 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -26.55% mean?
Tandem Diabetes Care (LTS:0M0F) has a ROC (Joel Greenblatt) % of -26.55% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tandem Diabetes Care and its competitors. According to the industry distribution chart, Tandem Diabetes Care ranks #565 out of 838 companies in the Medical Devices & Instruments industry, placing it in the top 67.4%.
Is Tandem Diabetes Care's ROC (Joel Greenblatt) % too high?
Tandem Diabetes Care's current ROC (Joel Greenblatt) % is -26.55%. Based on the distribution chart, Tandem Diabetes Care ranks #565 out of 838 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's ROC (Joel Greenblatt) % compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #565 out of 838 companies for ROC (Joel Greenblatt) %. This places Tandem Diabetes Care in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 4.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.15, based on 838 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current ROC (Joel Greenblatt) % is -26.55%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.13, compared to a current price of $16.44 — trading 43.6% below its estimated fair value. The current ROC (Joel Greenblatt) % is -26.55%. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current ROC (Joel Greenblatt) % is -26.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of $16.44 is trading 43.6% below its estimated GF Value™ of $29.13. GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.

Key valuation signals for LTS:0M0F:

  • ROC (Joel Greenblatt) %: -26.55%
  • GF Value™: $29.13 vs. price of $16.44 (43.6% below fair value)
  • GF Score™: 68/100 with 5 warning signs

No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score

Get the complete analysis for LTS:0M0F

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.44
Price
$29.13
GF Value